{"id":479889,"date":"2020-04-17T11:10:01","date_gmt":"2020-04-17T11:10:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=479889"},"modified":"2020-04-17T11:10:01","modified_gmt":"2020-04-17T11:10:01","slug":"resistant-hypertension-clinical-trial-insight-pipeline-assessment-emerging-drugs-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/resistant-hypertension-clinical-trial-insight-pipeline-assessment-emerging-drugs-delveinsight_479889.html","title":{"rendered":"RESISTANT HYPERTENSION CLINICAL TRIAL INSIGHT, PIPELINE ASSESSMENT, EMERGING DRUGS | DELVEINSIGHT"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1587095478.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"RESISTANT HYPERTENSION CLINICAL TRIAL INSIGHT, PIPELINE ASSESSMENT, EMERGING DRUGS | DELVEINSIGHT\" src=\"https:\/\/www.abnewswire.com\/uploads\/1587095478.jpeg\" alt=\"RESISTANT HYPERTENSION CLINICAL TRIAL INSIGHT, PIPELINE ASSESSMENT, EMERGING DRUGS | DELVEINSIGHT\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>&#8220;Resistant Hypertension Pipeline Insight, 2020\u201d<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight has launched a report on &ldquo;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/resistant-hypertension-pipeline-insight?utm_source=Daily%20Science&amp;utm_medium=Ankit-Press%20Release&amp;utm_campaign=Resistant%20Hypertension\">Resistant Hypertension Pipeline Insight, 202<\/a>0<strong>&nbsp;<\/strong>&rdquo;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/resistant-hypertension-pipeline-insight?utm_source=Daily%20Science&amp;utm_medium=Ankit-Press%20Release&amp;utm_campaign=Resistant%20Hypertension\">Resistant Hypertension Pipeline Insight, 2020<\/a>&rdquo; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;<strong>Resistant Hypertension&nbsp;<\/strong>market. A detailed picture of the&nbsp;<strong>Resistant Hypertension&nbsp;<\/strong>pipeline landscape is provided, which includes the disease overview and&nbsp;<strong>Resistant Hypertension&nbsp;<\/strong>treatment guidelines.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The assessment part of the report embraces in-depth&nbsp;<strong>Resistant Hypertension&nbsp;<\/strong>commercial assessment and clinical assessment of the&nbsp;<strong>Resistant Hypertension&nbsp;<\/strong>pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology,&nbsp;<strong>Resistant Hypertension&nbsp;<\/strong>collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key companies working on Resistant Hypertension&nbsp;are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Idorsia Pharmaceuticals<\/li>\n<li>Quantum Genomics<\/li>\n<li>Novartis<\/li>\n<li>Relypsa<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And Many Others.<\/p>\n<p style=\"text-align: justify;\">The launch of the emerging therapies is expected to significantly impact the&nbsp;<strong>Resistant Hypertension&nbsp;<\/strong>treatment scenario in the upcoming years:-<\/p>\n<p style=\"text-align: justify;\"><strong>Drugs Covered:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Aprocitentan<\/li>\n<li>Firibastat<\/li>\n<li>LHW090<\/li>\n<li>Veltassa<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And Many Others.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/resistant-hypertension-pipeline-insight?utm_source=Daily%20Science&amp;utm_medium=Ankit-Press%20Release&amp;utm_campaign=Resistant%20Hypertension\">Request a Free Sample Report @&nbsp;https:\/\/www.delveinsight.com\/sample-request\/resistant-hypertension-pipeline-insight<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Resistant Hypertension&nbsp;Analytical Perspective by DelveInsight<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>In-depth Resistant Hypertension Commercial Assessment of products&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing\/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Resistant Hypertension Clinical Assessment of products&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The&nbsp;<strong>Resistant Hypertension&nbsp;<\/strong>report provides an overview of&nbsp;<em>therapeutic pipeline activity and therapeutic assessment of the products <\/em>by development stage, product type, route of administration, molecule type, and MOA type&nbsp;<em>for&nbsp;<\/em><strong>Resistant Hypertension&nbsp;<\/strong>across the complete product development cycle, including all clinical and nonclinical stages.<\/li>\n<li>It comprises of&nbsp;<em>detailed profiles of&nbsp;<\/em><strong>Resistant Hypertension&nbsp;<\/strong><em>therapeutic products<\/em>with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/li>\n<li>Detailed&nbsp;<strong>Resistant Hypertension&nbsp;<\/strong><em>research and development progress and trial details<\/em>, results wherever available, are also included in the pipeline study.<\/li>\n<li><em>Coverage of dormant and discontinued pipeline project<\/em>s along with the reasons if available across&nbsp;<strong>Resistant Hypertension<\/strong>.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Report highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>A better understanding of disease pathogenesis contributing to the development of novel therapeutics for&nbsp;<strong>Resistant Hypertension<\/strong>.<\/li>\n<li>In the coming years, the&nbsp;<strong>Resistant Hypertension&nbsp;<\/strong>market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.<\/li>\n<li>The companies and academics that are working to assess challenges and seek opportunities that could influence&nbsp;<strong>Resistant Hypertension&nbsp;<\/strong>R&amp;D. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/li>\n<li>A detailed portfolio of major pharma players who are involved in fueling the&nbsp;<strong>Resistant Hypertension&nbsp;<\/strong>treatment market. Several potential therapies for&nbsp;<strong>Resistant Hypertension&nbsp;<\/strong>are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the&nbsp;<strong>Resistant Hypertension&nbsp;<\/strong>market size in the coming years.<\/li>\n<li>Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of&nbsp;<strong>Resistant Hypertension<\/strong>) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/resistant-hypertension-pipeline-insight?utm_source=Daily%20Science&amp;utm_medium=Ankit-Press%20Release&amp;utm_campaign=Resistant%20Hypertension\">Request a Free Sample Report @&nbsp;https:\/\/www.delveinsight.com\/sample-request\/resistant-hypertension-pipeline-insight<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Questions<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>What are the current options for&nbsp;<strong>Resistant Hypertension<\/strong>treatment?<\/li>\n<li>How many companies are developing therapies for the treatment of&nbsp;<strong>Resistant Hypertension<\/strong>?<\/li>\n<li>What are the principal therapies developed by these companies in the industry?<\/li>\n<li>How many therapies are developed by each company for the treatment of&nbsp;<strong>Resistant Hypertension<\/strong>?<\/li>\n<li>How many&nbsp;<strong>Resistant Hypertension&nbsp;<\/strong>emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of&nbsp;<strong>Resistant Hypertension<\/strong>?<\/li>\n<li>Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?<\/li>\n<li>What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact&nbsp;<strong>Resistant Hypertension&nbsp;<\/strong>market?<\/li>\n<li>Which are the dormant and discontinued products and the reasons for the same?<\/li>\n<li>What is the unmet need for current therapies for the treatment of&nbsp;<strong>Resistant Hypertension<\/strong>?<\/li>\n<li>What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing&nbsp;<strong>Resistant Hypertension<\/strong>therapies?<\/li>\n<li>What are the clinical studies going on for&nbsp;<strong>Resistant Hypertension&nbsp;<\/strong>and their status?<\/li>\n<li>What are the results of the clinical studies and their safety and efficacy?<\/li>\n<li>What are the key designations that have been granted for the emerging therapies for&nbsp;<strong>Resistant Hypertension<\/strong>?<\/li>\n<li>How many patents are granted and pending for the emerging therapies for the treatment of&nbsp;<strong>Resistant Hypertension<\/strong>?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/resistant-hypertension-pipeline-insight?utm_source=Daily%20Science&amp;utm_medium=Ankit-Press%20Release&amp;utm_campaign=Resistant%20Hypertension\">Request a Free Sample Report @&nbsp;https:\/\/www.delveinsight.com\/sample-request\/resistant-hypertension-pipeline-insight<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1. Report Introduction<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>2. Resistant Hypertension&nbsp;<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">2.1. Overview<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">2.2. History<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">2.3. Resistant Hypertension Symptoms<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">2.4. Causes<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">2.5.Pathophysiology<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">2.6. Resistant Hypertension Diagnosis<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">2.6.1. Diagnostic Guidelines<\/p>\n<p style=\"text-align: justify;\"><strong>3. Resistant Hypertension&nbsp;Current Treatment Patterns<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">3.1. Resistant Hypertension Treatment Guidelines<\/p>\n<p style=\"text-align: justify;\"><strong>4. Resistant Hypertension&nbsp;&ndash; DelveInsight&rsquo;s Analytical Perspective<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1. In-depth Commercial Assessment<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1.1. Resistant Hypertension&nbsp;companies collaborations, Licensing, Acquisition -Deal Value Trends<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1.1.1. Assessment Summary<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1.2. Resistant Hypertension&nbsp;Collaboration Deals<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1.2.1. Company-Company Collaborations (Licensing \/ Partnering) Analysis<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1.2.2. Company-University Collaborations (Licensing \/ Partnering) Analysis<\/p>\n<div class=\"google-auto-placed ap_container\" style=\"text-align: justify;\"><ins class=\"adsbygoogle adsbygoogle-noablate\" data-ad-format=\"auto\" data-ad-client=\"ca-pub-5258061401152217\" data-adsbygoogle-status=\"done\"><ins id=\"aswift_1_expand\"><ins id=\"aswift_1_anchor\"><\/ins><\/ins><\/ins><strong>5. Therapeutic Assessment<\/strong><\/div>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1. Clinical Assessment of Pipeline Drugs<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.1. Assessment by Phase of Development<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.2. Assessment by Product Type (Mono \/ Combination)<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.2.1. Assessment by Stage and Product Type<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.3. Assessment by Route of Administration<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.3.1. Assessment by Stage and Route of Administration<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.4. Assessment by Molecule Type<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.4.1. Assessment by Stage and Molecule Type<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.5. Assessment by MOA<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.5.1. Assessment by Stage and MOA<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.6. Assessment by Target<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1.6.1. Assessment by Stage and Target<\/p>\n<p style=\"text-align: justify;\"><strong>6. Resistant Hypertension Late Stage Products (Phase-III)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>7. Resistant Hypertension Mid Stage Products (Phase-II)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>8. Early Stage Products (Phase-I)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>9. Pre-clinical Products and Discovery Stage Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>10. Inactive Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>11. Dormant Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>12. Resistant Hypertension Discontinued Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>13. Resistant Hypertension&nbsp;Product Profiles<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1. Drug Name: Company<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.1. Product Description<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.1.1. Product Overview<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.1.2. Mechanism of action<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.2. Research and Development<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.2.1. Clinical Studies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.3. Product Development Activities<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.3.1. Collaboration<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.3.2. Agreements<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.3.3. Acquisition<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.3.4. Patent Detail<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.4. Tabulated Product Summary<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1.4.1. General Description Table<\/p>\n<p style=\"text-align: justify;\">Detailed information in the report?<\/p>\n<p style=\"text-align: justify;\"><strong>14. Resistant Hypertension&nbsp;Key Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>15. Resistant Hypertension&nbsp;Key Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>16. Dormant and Discontinued Products<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.1. Dormant Products<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.1.1. Reasons for being dormant<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.2. Discontinued Products<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.2.1. Reasons for the discontinuation<\/p>\n<p style=\"text-align: justify;\"><strong>17. Resistant Hypertension&nbsp;Unmet Needs<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>18. Resistant Hypertension&nbsp;Future Perspectives<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>19. Resistant Hypertension&nbsp;Analyst Review&nbsp;&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>20. Appendix<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>21. Report Methodology<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">21.1. Secondary Research<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">21.2. Expert Panel Validation<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=resistant-hypertension-clinical-trial-insight-pipeline-assessment-emerging-drugs-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=resistant-hypertension-clinical-trial-insight-pipeline-assessment-emerging-drugs-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Resistant Hypertension Pipeline Insight, 2020\u201d &nbsp; DelveInsight has launched a report on &ldquo;&nbsp;Resistant Hypertension Pipeline Insight, 2020&nbsp;&rdquo; &nbsp; &ldquo;Resistant Hypertension Pipeline Insight, 2020&rdquo; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;Resistant Hypertension&nbsp;market. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/resistant-hypertension-clinical-trial-insight-pipeline-assessment-emerging-drugs-delveinsight_479889.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,423,404,416],"tags":[],"class_list":["post-479889","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Professional-Services","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/479889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=479889"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/479889\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=479889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=479889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=479889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}